

Nicox SA

Société anonyme with a registered capital of € 812,367.85
Head Office: Sundesk Sophia Antipolis, Emerald Square, rue Evariste Galois – 06410 Biot
R.C.S. ANTIBES 403.942.642

On January 2, 2026,

MONTHLY PUBLICATION OF THE NUMBER OF SHARES COMPOSING THE SHARE CAPITAL AND OF THE TOTAL NUMBER OF VOTING RIGHTS

(Article 223-16 of the General Regulation of the AMF)

Market: Euronext Growth Paris

ISIN Code: FR0013018124

Website: www.nicox.com

As of December 31, 2025	
Total number of shares composing the share capital ⁽¹⁾	88,441,773
Total theoretical number of voting rights ⁽²⁾	88,441,773
Total effective number of voting rights ⁽³⁾	88,130,706

(1) Including 750,000 new shares issued during December 2025 as part of the equity financing line (see press release published on August 8, 2025).

(2) Theoretical voting rights are calculated on the basis of all shares to which voting rights are attached, including shares without voting rights, in accordance with Article 223-11 of the AMF's General Regulations.

(3) Effective voting rights correspond to the total number of voting rights exercisable at the General Meeting. They are calculated on the basis of the total number of voting rights attached to the total number of shares less shares without voting rights.

About Nicox

Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox's lead late-stage development program is NCX 470 (bimatoprost/grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, licensed to Ocumension Therapeutics for the Chinese, Korean and Southeast Asian markets and to Kowa in the rest of the world. Nicox also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Nicox's first product, VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets.

Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX).

For more information www.nicox.com

Analyst coverage

H.C. Wainwright & Co

Yi Chen

New York, U.S.



The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.

Contact

Nicox

Gavin Spencer
Chief Executive Officer
+33 (0)4 97 24 53 00
communications@nicox.com

www.nicox.com